|CD310||FLT4 (fms-related tyrosine kinase 4), VEGFR3 (vascular endothelial growth factor receptor-3)|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 1 glycoprotein
|146 / 146|
CD310 is expressed in placenta, lung, heart and kidney, but does not seem to be expressed in pancreas and brain. Expression is on lymphatic endothelium of normal and malignant tissues and on spindle cells of Kaposi's sarcoma.
|MOLECULAR FAMILY NAME: Belongs to the tyrosine protein kinase family.|
CD310 is a single-pass type-1 1274 aa glycoprotein. It contains a 24 aa signal sequence, a 751 aa extracellular domain which contains 7 Ig-like C2-type domains and 12 N-linked glycosylation sites, a transmembrane domain and a 501 aa intracellular cytoplasmic domain which contains a 329 aa protein kinase domain. CD310 together with CD308 and CD309 constitute the flt subfamily of receptors. CD310 is part of the type-3 tyrosine kinase receptors.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
CD310 has 12 N-linked glycoslation sites.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD310|
CD310 binds vascular endothelial growth factor (VEGF).
|CD310 has a tyrosine kinase activity. Ligand activated CD310 recruits CD192 (CKR2) and induces a signal cascade, resulting in the activation of c-Jun N-terminal kinase-1/2 (JNK1/2) and signaling for cell survival. Phosphorylation of tyrosines Y1230 and Y1231 leads to the recruitment of Grb2 which induces activation of AKT and ERK1/2 signaling and ultimately c-JUN expression and pro-survival signaling.|
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD310 IN INTACT ANIMAL
CD310 is a specific marker of lympathic endothelium and with VEGFD in gastric adencarcinoma patients correlates with a poor prognosis. Soluble CD310 decoy receptors are potential therapeutic agents for the prevention of metastasis via the lymphatic system for some tumors such as melamona and prostate cancer. CD310 is critical for angiogenesis in embryos and plays a role in angiogenesis and lymphangiogenesis in adults. Defects in CD310 are the cause of congenital heritary lymphedema known as Milroy disease which results in swelling of extremities due to altered lymphatic flow and also juvenile hemangioma causing tumors in infancy. Miroy disease is caused by autosomal dominant mutations and the onset of the lymphoedema can begin at birth and is severe enough to physically impair patients. Juvenile hemangiomas are related to CD310 mutations and are characterized by benign vascular lesions that expand in earlyu childhood but spontaneously involute over several years.
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD310: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD310: No information.
Database accession numbers
Revised June 25, 2008